TAVR-in-TAVR for Early Degeneration of a Novel Self-Expandable Valve Dedicated to Treatment of Aortic Regurgitation.

Competing Interests: Funding Support and Author Disclosures Dr Curio has received research grant support from Boston Scientific. Dr Wienemann has received travel grants from JenaValve. Dr Adam has received personal fees from Abbott, JenaValve, Medtronic, and Meril. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.